Fluticasone is associated with lower asthma-related costs than leukotriene modifiers in a real-world analysis

Pharmacotherapy

Volumn 22, Issue 9 I, 2002, Pages 1117-1123

  Armstrong, Edward P ^a   Malone, Daniel C ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUTICASONE; MONTELUKAST; ZAFIRLUKAST; ZILEUTON; ANDROSTANE DERIVATIVE; ANTIASTHMATIC AGENT; LEUKOTRIENE RECEPTOR BLOCKING AGENT;

ADULT; AGED; AIRWAY OBSTRUCTION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; BRONCHUS MUSCLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MULTIVARIATE ANALYSIS; SURVIVAL; ALGORITHM; ANALYSIS OF VARIANCE; COMPARATIVE STUDY; COST OF ILLNESS; ECONOMICS; HEALTH INSURANCE; RETROSPECTIVE STUDY; STATISTICAL MODEL; UNITED STATES;

ADULT; ALGORITHMS; ANALYSIS OF VARIANCE; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ARIZONA; ASTHMA; COST OF ILLNESS; FEMALE; HUMANS; LEUKOTRIENE ANTAGONISTS; LINEAR MODELS; MALE; MANAGED CARE PROGRAMS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 0036708213     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.22.13.1117.33515     Document Type: Article

References (33)

1. Asthma mortality and hospitalization among children and young adults - United States, 1980-1993
2. Trends in the cost of illness for asthma in the United States, 1985-1994
3. A national estimate of the economic costs of asthma
4. Analysis of asthma-related costs and patterns of resource utilization in a managed-care population
5. Health care utilization and cost among children with asthma who were enrolled in a health maintenance organization
6. The 1997 asthma guidelines and asthma clinical update
7. Comprehensive asthma management: Guidelines for clinicians
8. Corticosteroids and leukotrienes: Chronobiology and chronotherapy
9. Zafirlukast in clinical practice - Results of the accolate clinical experience and pharmacoepidemiology trial (ACCEPT) in patients with asthma
10. Effects of 2 weeks of treatment with fluticasone propionate 100 μg by comparison with zafirlukast 20 mg on bronchial hyper-responsiveness in patients with mild to moderate asthma
11. Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma
12. Pharmacoeconomic aspects of fluticasone propionate in the treatment of asthma
13. Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: A randomized trial
14. A chronic disease score from automated pharmacy data
15. Smearing estimate: A nonparametric retransformation method
16. Economic impact of asthma therapy with fluticasone propionate, montelukast, or zafirlukast in a managed care population
17. Low-dose inhaled corticosteroid and the prevention of death from asthma
18. A comparison of multiple doses of fluticasone propionate and beclomethasone dipropionate in subjects with persistent asthma
19. Fluticasone alone or in combination with salmeterol versus triamcinolone in asthma
20. Fluticasone propionate powder administered through Diskhaler versus triamcinolone acetonide aerosol administered through metered-dose inhaler in patients with persistent asthma
21. Differential effects of inhaled corticosteroids: Fluticasone propionate versus triamcinolone acetonide
22. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma: A randomized, controlled trial
23. A cost-effectiveness analysis of inhaled fluticasone propionate (Flovent) versus zafirlukast (Accolate) in the treatment of patients with persistent asthma
24. Cost-efficacy analysis of an inhaled corticosteroid versus a leukotriene receptor antagonist
25. Cost effectiveness of inhaled fluticasone versus zafirlukast in patients switched from low dose inhaled corticosteroids
26. Inhaled fluticasone propionate: A pharmacoeconomic review of its use in the management of asthma
27. Cost implications for the use of inhaled anti-inflammatory medications in the treatment of asthma
28. One-year claims analysis comparing inhaled fluticasone propionate with zafirlukast for the treatment of asthma
29. Comparison of asthma costs in patients starting fluticasone propionate compared to patients starting montelukast
30. A comparison of asthma-related expenditures for patients started on montelukast versus fluticasone propionate as monotherapy
31. Adherence to oral montelukast and inhaled fluticasone in children with persistent asthma